Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Running, not enrolling · Phase 1
Conditions studied: Non Hodgkin's Lymphoma, Large B-cell Lymphoma
In brief
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Key facts
- Study ID
- NCT06285422
- Run by
- Sana Biotechnology
- People needed
- 6
- Starts
- 2024-04-18
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2025-11-28
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or Female Subject aged 18-80 years at the time of signing the informed consent
- Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:
- LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B
- FL
- Marginal Zone Lymphomas (MZL)
- Mantle Cell Lymphoma (MCL)
- Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- At least 1 measurable (PET-positive) lesion per Lugano classification
- Life expectancy ≥12 Weeks
You may not qualify if…
- Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell)
- History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment.
- Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time)
- Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >10 mg/day prednisone or equivalent)
- History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment.
Where it is running
- The University of Kansas Hospital — Kansas City, Kansas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Fred Hutchinson Cancer Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.